PMV Pharmaceuticals (PMVP) Competitors $1.00 +0.01 (+1.01%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$1.04 +0.04 (+4.50%) As of 05/1/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMVP vs. CDTX, HUMA, DRUG, LFCR, ALMS, IMMP, CRVS, YMAB, FHTX, and PROKShould you be buying PMV Pharmaceuticals stock or one of its competitors? The main competitors of PMV Pharmaceuticals include Cidara Therapeutics (CDTX), Humacyte (HUMA), Bright Minds Biosciences (DRUG), Lifecore Biomedical (LFCR), Alumis (ALMS), Immutep (IMMP), Corvus Pharmaceuticals (CRVS), Y-mAbs Therapeutics (YMAB), Foghorn Therapeutics (FHTX), and ProKidney (PROK). These companies are all part of the "pharmaceutical products" industry. PMV Pharmaceuticals vs. Cidara Therapeutics Humacyte Bright Minds Biosciences Lifecore Biomedical Alumis Immutep Corvus Pharmaceuticals Y-mAbs Therapeutics Foghorn Therapeutics ProKidney PMV Pharmaceuticals (NASDAQ:PMVP) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, earnings, profitability, institutional ownership, media sentiment, valuation and risk. Which has more volatility & risk, PMVP or CDTX? PMV Pharmaceuticals has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Does the media refer more to PMVP or CDTX? In the previous week, Cidara Therapeutics had 5 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 8 mentions for Cidara Therapeutics and 3 mentions for PMV Pharmaceuticals. Cidara Therapeutics' average media sentiment score of 0.88 beat PMV Pharmaceuticals' score of 0.88 indicating that Cidara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PMV Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cidara Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor PMVP or CDTX? Cidara Therapeutics received 433 more outperform votes than PMV Pharmaceuticals when rated by MarketBeat users. Likewise, 70.31% of users gave Cidara Therapeutics an outperform vote while only 63.16% of users gave PMV Pharmaceuticals an outperform vote. CompanyUnderperformOutperformPMV PharmaceuticalsOutperform Votes2463.16% Underperform Votes1436.84% Cidara TherapeuticsOutperform Votes45770.31% Underperform Votes19329.69% Do analysts rate PMVP or CDTX? PMV Pharmaceuticals presently has a consensus target price of $5.67, indicating a potential upside of 466.67%. Cidara Therapeutics has a consensus target price of $39.14, indicating a potential upside of 79.97%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe PMV Pharmaceuticals is more favorable than Cidara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMV Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Which has preferable earnings & valuation, PMVP or CDTX? Cidara Therapeutics has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPMV PharmaceuticalsN/AN/A-$68.96M-$1.14-0.88Cidara Therapeutics$1.28M186.85-$22.93M-$30.09-0.72 Is PMVP or CDTX more profitable? PMV Pharmaceuticals has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -289.05%. PMV Pharmaceuticals' return on equity of -24.20% beat Cidara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PMV PharmaceuticalsN/A -24.20% -21.67% Cidara Therapeutics -289.05%-69.64%-33.73% Do institutionals and insiders hold more shares of PMVP or CDTX? 90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by company insiders. Comparatively, 7.6% of Cidara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryCidara Therapeutics beats PMV Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Get PMV Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMVP vs. The Competition Export to ExcelMetricPMV PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.95M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-1.007.3222.5118.54Price / SalesN/A241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book0.236.486.734.25Net Income-$68.96M$143.41M$3.22B$248.18M7 Day Performance-3.85%2.58%1.38%1.03%1 Month PerformanceN/A5.00%2.79%2.70%1 Year Performance-46.52%-3.72%15.41%4.05% PMV Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMVPPMV Pharmaceuticals2.2607 of 5 stars$1.00+1.0%$5.67+466.7%-46.2%$51.95MN/A-1.0050Upcoming EarningsNews CoverageGap UpCDTXCidara Therapeutics4.2409 of 5 stars$20.68+6.4%$39.14+89.3%+84.2%$226.51M$1.28M-0.8190Upcoming EarningsAnalyst ForecastNews CoverageHUMAHumacyte2.6606 of 5 stars$1.45-13.7%$13.71+845.8%-68.0%$224.92M$1.57M-1.08150News CoverageDRUGBright Minds Biosciences3.318 of 5 stars$31.89-3.7%$84.33+164.5%+2,844.2%$224.63MN/A-187.58N/ANews CoveragePositive NewsLFCRLifecore Biomedical1.6378 of 5 stars$6.04-5.8%$8.00+32.5%+6.1%$223.63M$130.86M-10.79690ALMSAlumis2.5177 of 5 stars$4.70-6.0%$26.00+453.2%N/A$221.94MN/A0.00N/AAnalyst ForecastGap DownIMMPImmutep1.7883 of 5 stars$1.51-1.9%$8.50+462.9%-35.8%$220.52M$5.14M0.002,021CRVSCorvus Pharmaceuticals2.5865 of 5 stars$3.22-0.6%$15.67+386.5%+118.6%$219.40MN/A-3.4630Upcoming EarningsHigh Trading VolumeYMABY-mAbs Therapeutics3.8106 of 5 stars$4.82+2.8%$18.30+279.7%-75.1%$217.95M$87.69M-8.93150Upcoming EarningsShort Interest ↓News CoverageFHTXFoghorn Therapeutics2.252 of 5 stars$3.90+2.6%$13.17+237.6%-29.0%$216.89M$22.60M-2.03120Upcoming EarningsAnalyst ForecastNews CoveragePROKProKidney2.3221 of 5 stars$0.73-7.3%$5.00+582.2%-60.5%$214.52M$76,000.00-1.333Positive NewsGap Up Related Companies and Tools Related Companies Cidara Therapeutics Alternatives Humacyte Alternatives Bright Minds Biosciences Alternatives Lifecore Biomedical Alternatives Alumis Alternatives Immutep Alternatives Corvus Pharmaceuticals Alternatives Y-mAbs Therapeutics Alternatives Foghorn Therapeutics Alternatives ProKidney Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMVP) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PMVP Stock Free PMVP Stock Alerts